Clinical Trials

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

NCT06222437 2026-03-23

Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

Polycystic Ovary Syndrome

NCT06282185 2026-03-23

Superman

Neoplasm Metastasis, Prostatic Neoplasms

NCT06713798 2026-03-23

INDIGO

Thoracic

Lung Neoplasms

NCT07217496 2026-03-17

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

Carcinoma, Transitional Cell

NCT07474844 2026-03-16

STRIkER

Colonic Polyps

NCT04953312 2026-03-12

CALPRO

MyeloidOther hematologic neoplasm

COVID-19, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT06229392 2026-03-11

A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer

Breast Neoplasms, Influenza, Human, Triple Negative Breast Neoplasms

NCT07137390 2026-03-11

A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer

Phase 1/2 Withdrawn

Colorectal Neoplasms

NCT03868475 2026-03-09

VAPEX

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Cicatrix, Phyllodes Tumor, Patient Satisfaction, Fibroadenoma

NCT06240377 2026-03-09

Effectiveness of NMP and TDCS vs Pharmacological Treatment in Cancer Patients With Lower Limb Pain

Cancer Pain, Neoplasms, Pain

NCT06240390 2026-03-09

Effectiveness of Percutaneous Neuromodulation vs Pharmacological Treatment in Cancer Patients With Anterior Knee Pain

Cancer Pain, Neoplasms, Pain

NCT06292975 2026-03-06

Exercise for Improving Radiotherapy Efficacy in Rectal Cancer

Motor Activity

NCT06710197 2026-03-05

OZM-034

Early Stage Triple Negative ER Low Breast Cancer

NCT07136571 2026-03-04

Phase I Study of Safety and Feasibility of Transarterial Embolization of Incurable Hypervascular Pediatric Soft Tissue Sarcomas

Sarcoma

NCT04243473 2026-03-03

Biopsy Collection for Men Undergoing Brachytherapy for Prostate Cancer

Withdrawn

Prostatic Neoplasms

NCT07439432 2026-02-27

Stereotactic Guided Biopsy and Cryoablation

Breast Neoplasms

NCT06796049 2026-02-25

Behavioral Nudge in Colorectal Cancer Screening

Improving Fecal Immunochemical Test (FIT) Completion Rates

NCT07223567 2026-02-25

A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer

Rectal Neoplasms

NCT05014295 2026-02-24

Patient Recall of Cancer Screening and Diagnosis

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT06297629 2026-02-24

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

Allogeneic Stem Cell Transplantation

NCT06522373 2026-02-24

Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease

Other hematologic neoplasm

Leukemia

NCT03905941 2026-02-23

SHK002

Phase EARLY_PHASE1 Withdrawn

Polycystic Ovary Syndrome

NCT06608940 2026-02-19

BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma

Phase 1/2 Withdrawn

Liver Neoplasms

NCT06217094 2026-02-18

Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment

Carcinoma, Hepatocellular

NCT06868238 2026-02-18

Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)

Carcinoma, Intraductal, Noninfiltrating, Lymphedema

NCT03027986 2026-02-17

PROTOMEN

Prostatic Neoplasms, Urinary Incontinence

NCT05487859 2026-02-17

Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)

Kidney Neoplasms

NCT05799612 2026-02-13

Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

Classical hematologyMyeloid

Sarcoma

Hemangiosarcoma

NCT06284460 2026-02-13

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Phase 1/2 Withdrawn

Anemia, Refractory, with Excess of Blasts, Myeloproliferative Disorders

NCT06585969 2026-02-12

DISCORDANT

Phase 3 Withdrawn

Breast Neoplasms

NCT05360745 2026-02-11

FOODPANC

Pancreatic Neoplasms

NCT05512260 2026-02-11

BESTa

BreastGastrointestinalGynecologic

Breast Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT06501989 2026-02-11

Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer